UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
February 10, 2014
Date of Report (Date of earliest event reported)
Auspex Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36292 | 95-4862842 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 3366 N. Torrey Pines Court, Suite 225 San Diego, CA | 92037 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 558-2400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
Amendment and Restatement of Certificate of Incorporation
On February 10, 2014, Auspex Pharmaceuticals, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of shares of its common stock. The Company’s board of directors and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the Company’s initial public offering.
A copy of the Restated Certificate is furnished herewith as Exhibit 3.1 and is incorporated herein by reference.
Amendment and Restatement of Bylaws
Effective as of February 10, 2014, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the Company’s initial public offering of shares of its common stock. The Company’s board of directors and stockholders previously approved the Restated Bylaws effective as of and contingent upon the closing of the Company’s initial public offering.
A copy of the Restated Bylaws is furnished herewith as Exhibit 3.2 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
Exhibit | Description | |
| 3.1 | Amended and Restated Certificate of Incorporation of Auspex Pharmaceuticals, Inc. | |
| 3.2 | Amended and Restated Bylaws of Auspex Pharmaceuticals, Inc. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Auspex Pharmaceuticals, Inc. | ||||
| Dated: February 11, 2014 | ||||
| By: | /s/ Pratik Shah | |||
| Pratik Shah, Ph.D. | ||||
| President and Chief Executive Officer | ||||
INDEX TO EXHIBITS
Exhibit | Description | |
| 3.1 | Amended and Restated Certificate of Incorporation of Auspex Pharmaceuticals, Inc. | |
| 3.2 | Amended and Restated Bylaws of Auspex Pharmaceuticals, Inc. | |
